Morbus KanzakiE75.2

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 19.05.2024

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Kanzaki et al, 1988

The first patient with this autosomal recessive disorder, a 46-year-old Japanese woman, presented with diffuse angiokeratoma, mild intellectual impairment and peripheral neuroaxonal degeneration. Transient expression of an alpha-GalNAc construct containing the R329W mutation resulted in the expression of an immunoreactive polypeptide that has no detectable alpha-GalNAc activity. Its accumulation leads to clinically heterogeneous symptoms ranging from asymptomatic individuals to individuals with severe neurological manifestations (Wang AM et al. 1994).

DefinitionThis section has been translated automatically.

Very rare, hereditary storage disease due to the absence of the lysosomal enzyme alpha-N-acetylgalactosaminidase

EtiopathogenesisThis section has been translated automatically.

The clinical picture is very closely related to the angiokeratoma corporis diffusum (Fabry's disease) and differs only slightly in the enzymatic activity of the enzyme alpha-N-acetylgalactosaminidase from that of alpha-galactosidase. This disorder is caused by a mutation of the N-acetyl-alpha-galactosaminidase gene [NAGA] on 22q11.

Clinical featuresThis section has been translated automatically.

Clinically very variable picture from absent clinic to lymphedema, hearing loss and cardiomegaly. Predominantly normal intelligence. The clinical picture is dermatologically conspicuous due to the occurrence of angiokeratoma corporis diffusum (analogous to Fabry disease).

LiteratureThis section has been translated automatically.

  1. Kanda A et al. (2002) Immunelectron microscopic analysis of lysosomal deposits in alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum. J Dermatol Sci 29: 42-48
  2. Kanzaki, T et al. (1988) Clinical and ultrastructural studies of novel angiokeratoma corporis diffusum. Clin Res 36: 377A
  3. Kanzaki T et al. (1989) Novel lysosomal glycoaminoacid storage disease with angiokeratoma corporis diffusum. Lancet 1: 875-876
  4. Kodama K et al. (2001) A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation. Br J Dermatol 144: 363-368
  5. Mohamed FE et al. (2020) A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity. J Mol Neurosci 70:45-55.
  6. Uchino Y (2003) Morphological and biochemical studies of human beta-mannosidosis: identification of a novel beta-mannosidase gene mutation. Br J Dermatol 149: 23-29
  7. Kanzaki T. (1995) Schindler disease/Kanzaki disease. Nihon Rinsho 53:2982-2987

  8. Wang AM et al. (1994) The molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes angiokeratoma corporis diffusum with glycopeptiduria. J Clin Invest 94:839-845.

  9. Yokota M et al. (1995) Histopathologic and ultrastructural studies of angiokeratoma corporis diffusum in Kanzaki disease. J Dermatol 22: 10-18

Authors

Last updated on: 19.05.2024